SynthesisInternational journal of environmental research and public health2023
Safety and Efficacy of Post-Eradication Smallpox Vaccine as an Mpox Vaccine: A Systematic Review with Meta-Analysis.
Synthesis in International journal of environmental research and public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Global perspectives on smallpox vaccine against monkeypox: a comprehensive meta-analysis and systematic review of effectiveness, protection, safety and cross-immunogenicity.Emerging microbes & infections · 2024Pooled it
- Exploration of the protein and pharmacological landscape of monkeypox virus treatment: from entry point to end point.Molecular diversity · 2026Review
- Monkey pox (Mpox): pathogenesis, genetic shifts, vaccination strategies and clinical insights.Archives of microbiology · 2026Review
- Mpox Infection and Endocrine Health: Bridging the Knowledge Gap.Medicina (Kaunas, Lithuania) · 2025Review
- Advancing the understanding and management of Mpox: insights into epidemiology, disease pathways, prevention, and therapeutic strategies.BMC infectious diseases · 2025Review
- "Mpox in MSM: Tackling stigma, minimizing risk factors, exploring pathogenesis, and treatment approaches".Biomedical journal · 2025Review
- Assessment of healthcare workers knowledge and attitudes towards Mpox infection at University of Gondar Comprehensive Specialized Referral Hospital, Ethiopia.Frontiers in public health · 2025Article
- Review
- Analysis of binding and authentic virus-neutralizing activities of immune sera induced by various monkeypox virus antigens.Immunologic research · 2024Article
- A Reemerging Disease: Could Mpox be a Pandemic Threat?Journal of clinical practice and research · 2024Article
- [Descriptive study of events allegedly attributable to mpox vaccination in Brazil in 2023].Cadernos de saude publica · 2024Article
- Serosurvey of Immunity to Monkeypox (Mpox) Virus Antigens in People Living with HIV in South Florida.Pathogens (Basel, Switzerland) · 2023Article
- Mpox: Clinical Outcomes and Impact of Vaccination in People with and without HIV: A Population-Wide Study.Microorganisms · 2023Article
- Article
- Review
- Epidemiological and Clinical Characteristics of Patients Admitted to a Secondary Hospital with Suspected MPOX Virus Infection: Is HIV Playing a Role?Journal of clinical medicine · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
According to the World Health Organization, 83,339 laboratory-confirmed cases, including 72 deaths, of mpox (formerly known as monkeypox), have been reported from 110 locations globally as of 20 December 2022, making the disease a public health concern. Most of the cases (56,171, 67.4%) were reported from countries in North America. Limited data on vaccine effectiveness in the current mpox outbreak are available. However, the modified vaccinia virus (smallpox vaccine) has been predicted to prevent or reduce the severity of the mpox infection. The present study of systematic review and meta-analysis aimed to evaluate the modified vaccinia vaccine's safety and efficacy on mpox by using reported randomized clinical trials. Following guidelines from the Cochrane Collaboration and PRISMA, multiple databases including PubMed, PLOS ONE, Google Scholar, British Medical Journal, and the U. S. National Library of Medicine were searched. Out of 13,294 research articles initially identified, 187 were screened after removing duplicates. Following the inclusion and exclusion criteria, the meta-analysis included ten studies with 7430 patients. Three researchers independently assessed the risk of bias in the included study. The pooled results suggest that the vaccinia-exposed group had fewer side effects when compared to the vaccinia naïve group (odds ratio: 1.66; 95% CI: 1.07-2.57;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.